Pharmaceutical Investing Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat
Pharmaceutical Investing FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
